Regenicin Inc.
Regenicin, Inc. focuses on developing and commercializing the technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company's products are used to restore the qualities of hea… Read more
Market Cap & Net Worth: Regenicin Inc. (RGIN)
Regenicin Inc. (PINK:RGIN) has a market capitalization of $15.35K ($15.35K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #44601 globally and #14113 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regenicin Inc.'s stock price $0.00 by its total outstanding shares 153483050 (153.48 Million).
Regenicin Inc. Market Cap History: 2015 to 2025
Regenicin Inc.'s market capitalization history from 2015 to 2025. Data shows change from $3.21 Million to $15.35K (-42.02% CAGR).
Regenicin Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regenicin Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RGIN by Market Capitalization
Companies near Regenicin Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Regenicin Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Regenicin Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, Regenicin Inc.'s market cap moved from $3.21 Million to $ 15.35K, with a yearly change of -42.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $15.35K | 0.00% |
| 2024 | $15.35K | 0.00% |
| 2023 | $15.35K | -80.00% |
| 2022 | $76.74K | -95.83% |
| 2021 | $1.84 Million | -21.05% |
| 2020 | $2.33 Million | +43.40% |
| 2019 | $1.63 Million | -33.33% |
| 2018 | $2.44 Million | -87.28% |
| 2017 | $19.19 Million | +8.70% |
| 2016 | $17.65 Million | +450.24% |
| 2015 | $3.21 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Regenicin Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.35K USD |
| MoneyControl | $15.35K USD |
| MarketWatch | $15.35K USD |
| marketcap.company | $15.35K USD |
| Reuters | $15.35K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.